Loading...
XNAS
ICLR
Market cap11bUSD
Jun 18, Last price  
146.00USD
1D
1.91%
1Q
46.44%
Jan 2017
94.15%
Name

ICON PLC

Chart & Performance

D1W1MN
XNAS:ICLR chart
P/E
14.12
P/S
1.35
EPS
10.34
Div Yield, %
Shrs. gr., 5y
8.85%
Rev. gr., 5y
24.17%
Revenues
8.25b
-0.37%
455,597,000630,722,000865,248,000887,612,000900,044,000945,729,0001,115,006,0001,336,058,0001,503,316,0001,574,978,0001,666,487,0001,758,439,0002,595,777,0002,805,839,0002,797,288,0005,480,826,0007,741,386,0008,120,176,0008,281,676,0008,251,340,000
Net income
229m
-71.02%
38,304,00055,963,00078,120,00094,299,00087,071,00022,880,00058,346,000102,812,000172,468,000239,539,000262,179,000272,944,000322,817,000373,986,000327,809,000153,185,000505,304,000612,335,000791,474,000229,339,000
CFO
1.04b
-19.47%
50,452,00042,966,00081,282,000255,070,00087,428,00020,191,000113,771,000221,227,000169,948,000279,531,000259,204,00048,741,000264,013,000412,541,000594,724,000829,142,000563,315,0001,161,027,0001,286,652,0001,036,205,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ICON Public Limited Company operates as a global clinical research organization (CRO), delivering outsourced development and commercialization services across Ireland, continental Europe, the United States, and various other international regions. The firm excels in the strategic design, execution, and analytical oversight of programs that facilitate the entire spectrum of clinical trials, from initial compound identification through all phases (I-IV) of human studies. Its comprehensive suite of clinical development offerings encompasses early-stage drug development, strategies for patient enrollment and retention, strategic planning and data analysis, late-phase investigations, cutting-edge data and technology platforms, and expert consulting. Additionally, ICON provides specialized medical imaging, clinical research, and laboratory services; meticulous project management; efficient site monitoring and administration; robust data management; biostatistical analysis and programming; professional medical writing and publication support; medical affairs expertise; independent endpoint adjudication and data monitoring committee services; vigilant pharmacovigilance; interactive response technologies (IRT); streamlined clinical supplies logistics; strategic regulatory guidance; impactful medical communication; and broad advisory services. ICON's diverse clientele includes companies across the pharmaceutical, biotechnology, and medical device sectors, alongside governmental and public health bodies. Established in 1990, the company maintains its headquarters in Dublin, Ireland.
IPO date
May 15, 1998
Employees
41,160
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT